NVX-108 is an oxygen therapeutic for life-threatening conditions like cancer and heart attack. Previously approved in Europe as an ultrasound contrast agent, it's now ready for human clinical trials after successful animal studies. Safe in humans and effective in treating ischemic/hypoxic diseases, this startup is poised for success.
NuvOx Pharma data powered by:
Share
NuvOx Pharma data powered by:
NuvOx PharmaOverall Ranking
National Rank
Share
Loading...
In United States
Top null%out of startups
Regional Rank
Share
Loading...
In North America
Top null%out of startups
NuvOx PharmaIndustry Rankings in
Healthtech
City Rank
Share
Loading...
In Tucson
Top null%out of startups
National Rank
Share
Loading...
In United States
Top null%out of startups
Regional Rank
Share
Loading...
In North America
Top null%out of startups
NuvOx PharmaSubindustry Rankings in
BiotechnologyCity Rank
Share
Loading...
In Tucson
Top null%out of startups
National Rank
Share
Loading...
In United States
Top null%out of startups
Regional Rank
Share
Loading...
In North America
Top null%out of startups
rankings by:
NuvOx PharmaSB Rank Evolution
Not enough data points to display the chart.
NuvOx PharmastartupComparison
National Ranking (undefined)
Loading...
...
Regional Ranking (undefined)
Loading...
...
Global Ranking (WorldWide)
Loading...
...
Industry Ranking (undefined)
Loading...
...
SubIndustry Ranking (undefined)
Loading...
...
See all ranked entities with a premium subscription
Get Pro